Our data showed that ATRA suppressed the cell proliferation of tamoxifen-resistant breast cancer cells, and effectively reduced the tumor growth of tamoxifen-resistant xenografts by promoting ERα degradation, decreasing ERα transactivation, and inhibits the activation of ERK1/2 and AKT. Here, ESR1 is linked to breast carcinoma.